Journal of Clinical Medicine (Nov 2022)

Reversible Bronchial Obstruction in Primary Ciliary Dyskinesia

  • Hagit Levine,
  • Ophir Bar-On,
  • Vered Nir,
  • Nicole West,
  • Yotam Dizitzer,
  • Huda Mussaffi,
  • Dario Prais

DOI
https://doi.org/10.3390/jcm11226791
Journal volume & issue
Vol. 11, no. 22
p. 6791

Abstract

Read online

Background: Inhaled bronchodilators are frequently used among patients with primary ciliary dyskinesia (PCD), although neither the effectiveness nor the prevalence of their use is known, due to the paucity of relevant studies. Methods: This is a retrospective analysis of pre- and post-bronchodilator spirometry results, of patients with PCD from two centers. Correlations were examined of bronchodilator response, with asthma and atopy markers. Results: Of 115 patients, 46 (40%) completed spirometry pre- and post-bronchodilation. Of these, 26 (56.5%) demonstrated reversible airway obstruction (increase in %FEV1 predicted ≥ 10%). Obstruction reversibility was not found to be associated with a family history of asthma, blood eosinophil level, elevated IgE, or atopy symptoms. Of the 46 patients who completed bronchodilator spirometry, 29 (63%) were regularly using bronchodilators and inhaled corticosteroids. Conclusions: More than half of patients with PCD presented with reversible airway obstruction, without any correlation to markers of personal or familial atopy. Inhaled bronchodilators and corticosteroid therapies are commonly used for treating PCD. Evaluating bronchodilator response should be considered, and its effectiveness should be further studied.

Keywords